Teva Pharmaceuticals is proud to announce a major milestone: our investigational anti-IL-15 antibody, TEV-53408, has received Fast Track designation from the US FDA for the treatment of celiac disease in patients on a gluten-free diet. Celiac disease affects nearly 1% of the global population, and many patients continue to experience debilitating symptoms despite strict dietary adherence. TEV-53408, now in Phase 2a trials, is designed to inhibit interleukin-15 (IL-15), aiming to reduce immune response and prevent intestinal damage caused by gluten exposure. This recognition by the FDA underscores both the urgent unmet needs in celiac disease and the innovative potential of our pipeline. At Teva, we remain committed to advancing treatments that transform lives for those living with chronic autoimmune conditions. Discover more about our commitment to innovation: https://lnkd.in/gxgTtzzr #CeliacDisease #FDA #FastTrack #TevaPharma #Innovation #AutoimmuneDisease #ClinicalTrials #Biotech #Healthcare #PatientCare #MedicalInnovation #Immunology #GlutenFree #R&D #PharmaNews
